Skip to main content
Clinical Trials/IRCT20130811014330N9
IRCT20130811014330N9
Recruiting
Phase 3

The use of human stromal vascular fraction(SVF) and platelet-rich plasma(PRP) in treatment of therapy-resistant diabetic foot ulcers: a randomized control trial phase III

Mashhad University of Medical Sciences0 sites20 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Mashhad University of Medical Sciences
Enrollment
20
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Having a diabetic ulcer grade 1 to 4 according to Wagner's classification
  • Having a single wound in the legs and extremities (fingers, soles, heels, on the toes) that has been at least 4 weeks old
  • No smoking, alcohol and drug addiction
  • Not taking drugs that may interfere with wound healing, such as corticosteroids, immunosuppressive agents, and cytotoxic agents
  • Not having concurrent diseases such as cancers, vasculitis, kidney and liver failure, and heart failure that may cause problems in wound healing
  • Informed consent of patients

Exclusion Criteria

  • Patients with acute bone inflammation or osteomyelitis
  • A wound with visible bone in the target area of treatment
  • Infected diabetic foot ulcers
  • Charcot deformity
  • History of treatment with chemotherapy drugs or radiation therapy in 3 months before the start of treatment
  • Hemoglobin less than 10mg/dL
  • History of treatment with growth factors during two weeks before starting treatment
  • Patients with less than 100,000 platelets
  • Vascular problems should not be observed in the wound (not ABI?0\.7\)

Outcomes

Primary Outcomes

Not specified

Similar Trials